Impact of Bempedoic acid on LDL-C reduction and cardiovascular outcomes: A comprehensive meta-analysis of randomized controlled trials.

Autor: Del Carpio-Tenorio C; Southern Medical Group, Cardiology Department, Tallahassee, United States. Electronic address: crdel@southern-med.com., Llerena-Velastegui J; Pontifical Catholic University of Ecuador, Medical School, Quito, Ecuador., Villacis-Lopez C; Central University of Ecuador, Medical School, Quito, Ecuador., Placencia-Silva M; Equinoctial Technological University, Medical School, Quito, Ecuador., Santander-Fuentes C; San Francisco University of Quito, Medical School, Quito, Ecuador., Benitez-Acosta K; La Sabana University, Medical School, Bogota, Colombia., Sanahuja-Montiel C; University of Medical Sciences, Medical School, San Jose, Costa Rica., Dominguez-Gavilanes D; Central University of Ecuador, Medical School, Quito, Ecuador., Carrasco-Perez P; Central University of Ecuador, Medical School, Quito, Ecuador., Calderon-Lopez C; Central University of Ecuador, Medical School, Quito, Ecuador.
Jazyk: angličtina
Zdroj: Current problems in cardiology [Curr Probl Cardiol] 2024 Feb; Vol. 49 (2), pp. 102191. Date of Electronic Publication: 2023 Nov 17.
DOI: 10.1016/j.cpcardiol.2023.102191
Abstrakt: Background: The management of LDL-C levels is pivotal in the prevention of cardiovascular morbidity, particularly among patients at high risk or those intolerant to statins. Bempedoic acid emerges as a novel agent in this therapeutic arena.
Objectives: This systematic review and meta-analysis endeavor to quantify the effectiveness of Bempedoic acid in attenuating LDL-C levels and explore its impact on cardiovascular morbidity, emphasizing its role as an adjunctive or alternative therapy in statin-intolerant or high-risk patients.
Methods: A comprehensive search spanning PubMed, Google Scholar, and Cochrane Library databases furnished studies for this review. The inclusion was critiqued based on predefined PICOS parameters, ensuring a robust analytical framework.
Results: Bempedoic acid showcased a significant plunge in LDL-C levels (MD -20.69 %, 95 % CI [-23.20, -18.19]), outperforming placebo and ezetimibe monotherapy. The cardioprotective effect was further echoed with a reduced risk of major adverse cardiac events (MACE) in the Bempedoic acid cohort (RR 0.86, 95 % CI [0.80, 0.94]). However, a dive into the safety profile revealed no substantial augmentation in adverse events, affirming its tolerance and efficacy.
Conclusions: Bempedoic acid represents a potent therapeutic ally, affirming its capacity to significantly pare down LDL-C levels and curtail cardiovascular events. Its favorable safety profile underscores its suitability, especially among those with statin intolerance or individuals categorized within the high-risk vascular bracket, necessitating a paradigm shift in current lipid management strategies.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: